🔗 Share this article

As the US proceeds with unprecedented changes to its vaccine guidelines, one figure has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who first made her name by expressing skepticism about coronavirus vaccinations during the global health crisis and has focused upon possible fatalities following COVID-19 immunization in her brief time at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Vaccine Schedule

Health officials had intended to reveal radical changes to the pediatric vaccine schedule recently, bringing the US with Denmark’s vaccine program, it is understood – a major change that would place the US at odds with much of the international standard with insufficient data for improved outcomes. The planned update has been pushed back until the coming year.

Rather than the director of the vaccine center, Dr. Høeg is scheduled to present at the meeting. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth individual to head the center this calendar year.

A New Direction at the Regulatory Body

This interim role might represent a strengthened alliance between the pharmaceutical and biologics divisions as Høeg and Prasad solidify control at the agency – and it points to a greater focus upon rolling back long-standing vaccines at the FDA.

Dr. Høeg has often pushed for halting certain pediatric shot schedules in the US in order to be more in line with Denmark, a country with comprehensive healthcare and a population approximately the population of the state of Wisconsin.

So far statements, she has continued to focus on vaccination policy – typically the domain of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Doubts Over Background

Dr. Høeg has no apparent background in drug development, oversight or management, which has been customary for former leaders of the CBER. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“She doesn’t seem to have the requisite experience” for overseeing the drug-regulation department, stated a neurologist and psychiatrist. “She’s never run a clinical trial. She lacks experience in leading a major agency. She is not an expert in industry regulation.”

Past directors of the center would “understand laws and regulations and the underlying principles of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Frankly, she doesn’t have the sort of resume that prior appointees who headed CBER have had.”

The drug center has an enormous workload at the FDA, she pointed out.

“The public just zeroes in on the novel medication approvals, but the off-patent medication office authorizes numerous off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and more, and every single one must be managed,” Woodcock said. “The area you neglect, that’s the thing that I always told people is going to bite you.”

There is also, a significant management component to the job, which manages over 5,000 employees. “It is a massive management job, if you perform it correctly,” she said.

Response and Controversial Policies

Regarding questions about Dr. Høeg's fitness for the role and whether this selection signifies greater collaboration among regulatory chiefs on immunizations, a press secretary said that the “inquiries stem from inaccurate premises”.

“Her resume aligns with the duties of her position,” the spokesperson said, noting the period Høeg spent advising the agency head on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg inherits the agency head's controversial priority voucher program, a disputed rapid drug-approval program that allegedly troubled her predecessors. “By what process are these therapies being selected for this voucher program? Who is making the decisions?” Howard said. “There’s a lot of secrecy occurring at the FDA right now.”

In general, he said, “the FDA looks to be trending towards more relaxed oversight of pharmaceuticals, with the exception of vaccines.”

Public Track Record on Immunizations

With vaccines, Høeg has a clearer, if problematic, history, some experts observe. She authored a research paper using unconfirmed volunteer-provided data to assess the incidence of heart inflammation following Covid vaccination. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccines are pose a greater threat than they are.

Among her “wish list” for the current federal leadership included revising rules for recently developed shots and discontinuing “optional” vaccines, she remarked post-election on a podcast. At the FDA, Høeg has according to sources suggested barring adolescent males from obtaining Covid vaccines.

“She’s an all-around true believer who commences with her conclusions and works backwards to retrofit the science in a very deceptive, fraudulent manner,” Howard stated.

Consolidating Power and a “Campaign of Retribution”

Høeg joined other dissenters, {like|